XML 95 R41.htm IDEA: XBRL DOCUMENT
v2.4.0.8

18. Pro Forma Financials for Acquisition of Canterbury, Hygeia, Paloma and VasculoMedics (Tables) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2014 | Dec. 31, 2013
Pro Forma Financials For Acquisition Of Canterbury Hygeia Paloma And Vasculomedics Tables |  |
Business Acquisition, Proforma Information | RestorGenex Corporation, Canterbury and Hygeia Pro Forma Statements of Operations Three Months Ended March 31, 2014
|  | Three Months Ended March 31, 2014 (a) |
|  |  |  |  |  |  |  |  |  |  | Pro Forma |  |  | Pro Forma |
|  | RestorGenex |  |  | Paloma |  |  | VasculoMedics |  |  | Adjustments |  |  | Combined |
Revenues |  | $ | – |  |  | $ | – |  |  | $ | – |  |  | $ | – |  |  | $ | – |
Cost of revenues |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Gross profit |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
General, administrative, research and development |  |  | 611,845 |  |  |  | 102,153 |  |  |  | – |  |  |  | 81,250 | (b) |  |  | 795,248 |
Warrants, options and stock compensation |  |  | 149,885 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 149,885 |
Legal and professional services |  |  | 131,686 |  |  |  | 1,725 |  |  |  | – |  |  |  | – |  |  |  | 133,411 |
Depreciation and amortization |  |  | 478,104 |  |  |  | 634 |  |  |  | – |  |  |  | 27,755 | (c) |  |  | 506,493 |
Total operating expenses |  |  | 1,371,520 |  |  |  | 104,512 |  |  |  | – |  |  |  | 109,005 |  |  |  | 1,585,037 |
Loss from operations |  |  | (1,371,520 | ) |  |  | (104,512 | ) |  |  | – |  |  |  | (109,005 | ) |  |  | (1,585,037 | )
Other (income)/expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other income |  |  | (49,639 | ) |  |  | (25,397 | ) |  |  | – |  |  |  | – |  |  |  | (75,036 | )
Interest expense |  |  | 58,294 |  |  |  | 29,925 |  |  |  | – |  |  |  | – |  |  |  | 88,219 |
Total other expenses |  |  | 8,655 |  |  |  | 4,528 |  |  |  | – |  |  |  | – |  |  |  | 13,183 |
Net loss from continuing operations |  |  | (1,380,175 | ) |  |  | (109,040 | ) |  |  | – |  |  |  | (109,005 | ) |  |  | (1,598,220 | )
Net loss from discontinued operations |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Net loss |  | $ | (1,380,175 | ) |  | $ | (109,040 | ) |  | $ | – |  |  | $ | (109,005 | ) |  | $ | (1,598,220 | )
Basic and diluted loss per share |  | $ | (0.23 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  | $ | (0.18 | )
Basic and fully-diluted weighted average shares outstanding |  |  | 5,934,474 |  |  |  | 2,500,000 | (d) |  |  | 220,000 | (d) |  |  | – |  |  |  | 8,654,474 |
(a) | Assumes the mergers with Paloma and VasculoMedics occurred on January 1, 2014.
(b) | Impact of employment agreements from January 1, 2014 to March 31, 2014.
(c) | Amortization of intangible assets for Paloma assuming a 20-year amortization period.
(d) | Impact on weighted average shares outstanding for the acquisition shares being outstanding for the entire quarter.
RestorGenex Corporation, Canterbury, Hygeia, Paloma and VasculoMedics Pro Forma Statements of Operations Three Months Ended March 31, 2013
|  | Three Months Ended March 31, 2013 (a) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Pro Forma |  |  | Pro Forma |
|  | RestorGenex |  |  | Canterbury |  |  | Hygeia |  |  | Paloma |  |  | VasculoMedics |  |  | Adjustments |  |  | Combined |
Revenues |  | $ | – |  |  | $ | 46,155 |  |  | $ | – |  |  | $ | – |  |  | $ | – |  |  | $ | – |  |  | $ | 46,155 |
Cost of revenues |  |  | – |  |  |  | 54,765 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 54,765 |
Gross profit |  |  | – |  |  |  | (8,610 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (8,610 | )
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
General, administrative, research and development |  |  | 624,674 |  |  |  | 31,331 |  |  |  | – |  |  |  | 47,880 |  |  |  | – |  |  |  | 848,732 | (b) |  |  | 1,552,617 |
Warrants, options and stock |  |  | 1,316,148 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 1,316,148 |
Legal and professional services |  |  | 143,103 |  |  |  | 25,435 |  |  |  | – |  |  |  | 17,254 |  |  |  | – |  |  |  | – |  |  |  | 185,792 |
Depreciation and amortization |  |  | 8,687 |  |  |  | 4,212 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 687,713 | (c) |  |  | 700,612 |
Total operating expenses |  |  | 2,092,612 |  |  |  | 60,978 |  |  |  | – |  |  |  | 65,134 |  |  |  | – |  |  |  | 1,536,445 |  |  |  | 3,755,169 |
Loss from operations |  |  | (2,092,612 | ) |  |  | (69,588 | ) |  |  | – |  |  |  | (65,134 | ) |  |  | – |  |  |  | (1,536,445 | ) |  |  | (3,763,779 | )
Other (income)/expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss on adjustments to fair value of derivative liability |  |  | 236,850 |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 236,850 |
Other income |  |  | (2,564 | ) |  |  | – |  |  |  | – |  |  |  | (63,910 | ) |  |  | – |  |  |  | – |  |  |  | (66,474 | )
Interest expense |  |  | 22,971 |  |  |  | 2,358 |  |  |  | – |  |  |  | 20,781 |  |  |  | – |  |  |  | – |  |  |  | 46,110 |
Total other (income)/expenses |  |  | 257,257 |  |  |  | 2,358 |  |  |  | – |  |  |  | (43,129 | ) |  |  | – |  |  |  | – |  |  |  | (216,486 | )
Net loss from continuing operations |  |  | (2,349,869 | ) |  |  | (71,946 | ) |  |  | – |  |  |  | (22,005 | ) |  |  | – |  |  |  | (1,536,445 | ) |  |  | (3,980,265 | )
Net loss from discontinued operations |  |  | (126,911 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (126,911 | )
Net loss |  | $ | (2,476,780 | ) |  | $ | (71,946 | ) |  | $ | – |  |  | $ | (22,005 | ) |  | $ | – |  |  | $ | (1,536,445 | ) |  | $ | (4,107,176 | )
Basic and diluted loss per share |  | $ | (2.77 | ) |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  | $ | (0.86 | )
Basic weighted average shares outstanding |  |  | 892,534 |  |  |  | 1,150,116 | (d) |  |  | – |  |  |  | 2,500,000 | (d) |  |  | 220,000 | (d) |  |  | – |  |  |  | 4,762,650 |
Fully-diluted weighted average shares outstanding |  |  | 1,207,534 |  |  |  | 1,150,116 | (d) |  |  | – |  |  |  | 2,500,000 | (d) |  |  | 220,000 | (d) |  |  | – |  |  |  | 5,077,650 |
(a) | Assumes the mergers with Canterbury, Hygeia, Paloma and VasculoMedics occurred on January 1, 2013.
(b) | Adds the $848,732 of expenses associated with employment agreements for Canterbury and Paloma executives that would be incurred from January 1, 2013.
(c) | Adds $659,958 of additional amortization for intangible assets at Canterbury and $27,755 for Paloma (assuming at 20-year amortization period) that would be incurred if amortization began on January 1, 2013.
(d) | Impact on weighted average shares if the 1,150,116 shares issued for the mergers with Canterbury and Hygeia, the 2,500,000 shares issued for the Paloma merger and the 220,000 shares issued for the VasculoMedics merger were outstanding for the quarter.
| RestorGenex Corporation, Canterbury and Hygeia Pro Forma Income Statements For the Year Ended December 31, 2013
|  | Year Ended December 31, 2013 (a) |  |  |  |
|  |  |  |  | Pro Forma |  |  |  |  |  |  |
|  |  |  |  |  | Adjustments |  |  | Other |  |  |  |  |
|  |  |  |  |  | for Canterbury |  |  | Pro Forma |  |  | Pro Forma |
|  | RestorGenex |  |  | and Hygeia (b) |  |  | Adjustments |  |  | Combined |
|  |  | (Audited) |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  | $ | 71,667 |  |  | $ | 127,167 |  |  | $ | – |  |  | $ | 198,834 |
Cost of revenues |  |  | – |  |  |  | 89,387 |  |  |  | – |  |  |  | 89,387 |
Gross profit |  |  | 71,667 |  |  |  | 37,780 |  |  |  | – |  |  |  | 109,447 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
General, administrative, research and development |  |  | 2,008,118 |  |  |  | 265,260 |  |  |  | 503,732 | (c) |  |  | 2,777,110 |
Impairment of intangible assets |  |  | 1,935,621 |  |  |  | – |  |  |  | – |  |  |  | 1,935,621 |
Warrants, options and stock |  |  | 4,228,317 |  |  |  | – |  |  |  | – |  |  |  | 4,228,317 |
Fair value of common stock exchanged for warrants |  |  | 3,069,792 |  |  |  | – |  |  |  | – |  |  |  | 3,069,792 |
Legal and professional services |  |  | 1,071,392 |  |  |  | 326,646 |  |  |  | – |  |  |  | 1,398,038 |
Depreciation and amortization |  |  | 675,757 |  |  |  | 14,781 |  |  |  | 659,958 | (d) |  |  | 1,350,496 |
Total operating expenses |  |  | 12,988,997 |  |  |  | 606,687 |  |  |  | 1,163,690 |  |  |  | 14,759,374 |
Loss from operations |  |  | (12,917,330 | ) |  |  | (568,907 | ) |  |  | (1,163,690 | ) |  |  | (14,649,927 | )
Other (income)/expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
(Gain)/loss on adjustments to fair value of derivative liability |  |  | (8,980,077 | ) |  |  | – |  |  |  | – |  |  |  | (8,980,077 | )
Gain on extinguishment of derivative liability |  |  | (1,183,093 | ) |  |  | – |  |  |  | – |  |  |  | (1,183,093 | )
Other (income)/expenses |  |  | (524,505 | ) |  |  | – |  |  |  | – |  |  |  | (524,505 | )
Interest expense |  |  | 228,294 |  |  |  | 20,267 |  |  |  | – |  |  |  | 248,561 |
Total other (income)/expenses |  |  | (10,459,381 | ) |  |  | 20,267 |  |  |  | – |  |  |  | (10,439,114 | )
Net loss |  |  | (2,457,949 | ) |  |  | (589,174 | ) |  |  | (1,163,690 | ) |  |  | (4,210,813 | )
Net loss attributed to non-controlling interests |  |  | (6,401 | ) |  |  | – |  |  |  | – |  |  |  | (6,401 | )
Net loss attributed to RestorGenex Corporation |  |  | (2,464,350 | ) |  |  | (589,174 | ) |  |  | (1,163,690 | ) |  |  | (4,217,214 | )
Preferred dividends |  |  | 171,625 |  |  |  | – |  |  |  | – |  |  |  | 171,625 |
Net income/(loss) attributable to RestorGenex Corporation common shareholders |  | $ | (2,635,975 | ) |  | $ | (589,174 | ) |  | $ | (1,163,690 | ) |  | $ | (4,388,839 | )
Basic and diluted earnings per share |  | $ | (1.00 | ) |  |  |  |  |  |  |  |  |  | $ | (1.20 | )
Basic and fully-diluted weighted average shares outstanding |  |  | 2,646,603 |  |  |  |  |  |  |  | 1,014,623 | (e) |  |  | 3,661,226 |
(a) | Assumes the mergers with Canterbury and Hygeia occurred on January 1, 2012.
(b) | Results of operations from January 1, 2013 to November 18, 2013, when the mergers were closed.
(c) | Impact of employment agreements from January 1, 2013 to November 18, 2013.
(d) | Impact of amortization of intangible assets from January 1, 2013 to November 18, 2013.
(e) | Impact on weighted average shares if the 1,150,116 shares issued for the mergers were outstanding for the full year.
If the Mergers had occurred on January 1, 2012, the combined statement of operations for the year ended December 31, 2012 would be as follows: RestorGenex Corporation, Canterbury and Hygeia Pro Forma Income Statements For the Year Ended December 31, 2012
|  | Year Ended December 31, 2012 (a) |  |  |  |
|  |  |  |  |  |  |  | Other |  |  |  |
|  |  |  |  | Canterbury |  |  | Pro Forma |  |  | Pro Forma |
|  | RestorGenex |  |  | and Hygeia |  |  | Adjustments |  |  | Combined |
|  | (Audited) |  |  |  |  |  |  |  |  |  |
Revenues |  | $ | 374,542 |  |  | $ | 246,731 |  |  | $ | – |  |  | $ | 621,273 |
Cost of revenues |  |  | 235,803 |  |  |  | 123,374 |  |  |  | – |  |  |  | 359,177 |
Gross profit |  |  | 138,739 |  |  |  | 123,357 |  |  |  | – |  |  |  | 262,096 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
General, administrative, research and development |  |  | 4,570,161 |  |  |  | 324,261 |  |  |  | 503,732 | (b) |  |  | 5,398,154 |
Impairment of intangible assets |  |  | 1,423,844 |  |  |  | – |  |  |  | – |  |  |  | 1,423,844 |
Warrants, options and stock |  |  | 3,643,662 |  |  |  | – |  |  |  | – |  |  |  | 3,643,662 |
Legal and professional services |  |  | 2,128,898 |  |  |  | 77,965 |  |  |  | – |  |  |  | 2,206,863 |
Depreciation and amortization |  |  | 164,043 |  |  |  | 17,196 |  |  |  | 747,276 | (c) |  |  | 928,515 |
Total operating expenses |  |  | 11,930,608 |  |  |  | 419,422 |  |  |  | 1,251,008 |  |  |  | 13,601,038 |
Loss from operations |  |  | (11,791,869 | ) |  |  | (296,065 | ) |  |  | (1,251,008 | ) |  |  | (13,338,942 | )
Other (income)/expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of derivative liabilities in excess of proceeds |  |  | 408,501 |  |  |  |  |  |  |  |  |  |  |  |  |
(Gain)/loss on adjustments to fair value of derivative liability |  |  | (6,907,748 | ) |  |  | – |  |  |  | – |  |  |  | (6,907,748 | )
Other (income)/expenses |  |  | 379,188 |  |  |  | – |  |  |  | – |  |  |  | 379,188 |
Present value of remaining lease payments for facilities no longer occupied |  |  | 1,010,111 |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense |  |  | 167,894 |  |  |  | – |  |  |  | – |  |  |  | 167,894 |
Total other (income)/expenses |  |  | (4,942,054 | ) |  |  | – |  |  |  | – |  |  |  | (6,360,666 | )
Net loss |  |  | (6,849,815 | ) |  |  | (296,065 | ) |  |  | (1,251,008 | ) |  |  | (6,978,276 | )
Net loss attributed to non-controlling interests |  |  | (19,079 | ) |  |  | – |  |  |  | – |  |  |  | (19,079 | )
Net loss attributed to RestorGenex Corporation |  |  | (6,868,894 | ) |  |  | (296,065 | ) |  |  | (1,251,008 | ) |  |  | (6,997,355 | )
Preferred dividends |  |  | 497,167 |  |  |  | – |  |  |  | – |  |  |  | 497,167 |
Net income/(loss) attributable to RestorGenex Corporation common shareholders |  | $ | (7,366,061 | ) |  | $ | (296,065 | ) |  | $ | (1,251,008 | ) |  | $ | (7,494,522 | )
Basic and diluted earnings per share |  | $ | (8.16 | ) |  |  |  |  |  |  |  |  |  | $ | (3.65 | )
Basic and fully-diluted weighted average shares outstanding |  |  | 903,139 |  |  |  |  |  |  |  | 1,150,116 | (d) |  |  | 2,053,255 |
Fully-diluted weighted average shares outstanding |  |  | 1,121,987 |  |  |  |  |  |  |  | 1,150,116 | (d) |  |  | 2,272,103 |
(a) | Assumes the mergers with Canterbury and Hygeia occurred on January 1, 2012.
(b) | Impact of employment agreements for the full year.
(c) | Impact of amortization of intangible assets for the full year.
(d) | Impact on weighted average shares if the 1,150,116 shares issued for the mergers were outstanding for the full year.

X
- Details
Name: | RESX_BusinessCombinationAbstract
Namespace Prefix: | RESX_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)-(3) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration